Infectious Outcomes of a Standardized Subcutaneous Immunoglobulin Dose Reduction Strategy in Primary Immune Deficiencies Amid Global Shortage

This retrospective study assessed the impact of a hospital’s implementation of a contingency plan adjusting the dosage of subcutaneous immunoglobulin in humoral primary immunodeficiency patients during a pandemic. The authors found that implementation of this protocol was successfully maintained without an increase in infection and that individualized dose reduction may be a safe and cost-effective approach during times when plasma-derived products are scarce.